

### Contents

1.	Overvie	W	1
2.	Vision a	nd Aims	1
	2.1	Medication safety vision	
	2.2	Three medication safety aims	1
3.	Five me	dication safety priorities	2
	3.1	Nurture a Safe and Just Culture	2
	3.2	Optimise Capacity and Capability	2
	3.3	Implement Electronic Medicines Management Systems	2
	3.4	Manage High Risk Areas	2
	3.5	Best care for everyone	2
Appe		edicines Management Pathway and its aligns with Waitemata DHB medication riorities	3
Appe		ignment of medication safety priorities with national, regional and local priorities	

#### 1. Overview

#### Purpose

This document outlines the strategy of the Medication Safety Group

#### Scope

DHB-wide perspective

### 2. Vision and Aims

#### 2.1 Medication safety vision

Our medication safety vision is to provide and be recognised as an organisation with reliable, resilient and responsive medication systems which achieves safe and patient-centred outcomes that are among the best in the world.

### 2.2 Three medication safety aims

To achieve our Medication Safety Vision, the DHB has set out three broad aims:

Waitemata DHB medication safety aims	How will we know if we are successful?				
1. Enhance the reliability, resiliency and responsiveness of Waitemata DHB medication systems to optimise medicines use	<ul> <li>Improve from a baseline ISMP-MSSA* score of 63% (FY2014-2015) to ≥65% by FY2018</li> </ul>				
2. Achieve safe outcomes	<ul> <li>To observe improved trends in medication related patient health outcomes<sup>#</sup> by FY2018</li> </ul>				
3. Achieve patient centred outcomes	• To improve patient experiences <sup>&amp;</sup> related to medication use by 80% by July 2018				
*ISMP-MSSA: Institute of Safe Medication Practice's Medication Safety Self-Assessment score <sup>#</sup> Defined as both adverse and beneficial consequences associated with medication use (e.g. errors, adverse drug events, falls, survival)					

Issued by	Director of Nursing & Midwifery	Issued Date	May 2016	Classification	01001-13-037
Authorised by	Chief Medical Officer	<b>Review Period</b>	36 months	Page	1 of 4



\*Defined by the following questions:

- a. Did a member of staff tell you about medication side effects to watch out for when you went home?
- b. Do you feel you received enough information from the hospital on how to manage your condition after your discharge?
- c. Were you involved as much as you wanted to be in decisions about your care and treatment?
- d. Overall, was the way staff involved you in decisions about your care very poor or very good (0-10)

## 3. Five medication safety priorities

To achieve these aims, we have identified five priorities which span across the entire medicines management pathway:

### 3.1 Nurture a Safe and Just Culture

To nurture and develop a collective and shared belief in the importance of, and commitment to, medication safety among all staff and demonstrated through leadership, caring, communicative, situationally aware, learning and non-punitive attitudes, mind-sets and behaviours

## 3.2 Optimise Capacity and Capability

To optimise physical environments, infrastructure and workforce training programs according to current professional knowledge to increase the likelihood of safe medication use

## 3.3 Implement Electronic Medicines Management Systems

Automation, interoperability and clinician decision support systems are feasibly implemented at all stages of the medicines use pathway wherever possible.

## 3.4 Manage High Risk Areas

There is a coordinated and targeted improvement system in place to identify, monitor, and manage high risk medicines areas to increase the likelihood of safe medicines use

### 3.5 Best care for everyone

Provision of patient centered care that is respectful and responsive to individual preferences, needs and value and where patients are empowered and actively participate in the use of medicines to achieve optimised health outcomes.

#### Notes:

The detailed action plan for FY2015-2018 has been attached as a separate A3 document

- **Appendix 1** outlines the five priorities and its alignment with the medicines management pathway.
- Appendix 2: show how the medication safety strategy 2015-2018 aligns with national, regional and local priorities

Issued by	Director of Nursing & Midwifery	Issued Date	May 2016	Classification	01001-13-037
Authorised by	Chief Medical Officer	<b>Review Period</b>	36 months	Page	2 of 4

### Appendix 1: Medicines Management Pathway and its aligns with Waitemata DHB medication safety priorities

#### Medication Safety Vision and Aims:

To provide and be recognised as an organisation with 1) reliable, resilient and responsive medication systems which achieves 2) safe and 3) patient-centred outcomes that are among the best in the world.



Issued by	Director of Nursing & Midwifery	Issued Date	May 2016	Classification	01001-13-037
Authorised by	Chief Medical Officer	<b>Review Period</b>	36 months	Page	<b>3</b> of <b>4</b>

Appendix 2: Alignment of medication safety priorities with national, regional and local priorities



Issued by	Director of Nursing & Midwifery	Issued Date	May 2016	Classification	01001-13-037
Authorised by	Chief Medical Officer	<b>Review Period</b>	36 months	Page	<b>4</b> of <b>4</b>